FXYD6: a novel therapeutic target toward hepatocellular carcinoma
Protein & Cell
;
(12): 532-543, 2014.
Article
in English
| WPRIM
| ID: wpr-757488
ABSTRACT
FXYD6, FXYD domain containing ion transport regulator 6, has been reported to affect the activity of Na(+)/K(+)-ATPase and be associated with mental diseases. Here, we demonstrate that FXYD6 is up-regulated in hepatocellular carcinoma (HCC) and enhances the migration and proliferation of HCC cells. Up-regulation of FXYD6 not only positively correlates with the increase of Na(+)/K(+)-ATPase but also coordinates with the activation of its downstream Src-ERK signaling pathway. More importantly, blocking FXYD6 by its functional antibody significantly inhibits the growth potential of the xenografted HCC tumors in mice, indicating that FXYD6 represents a potential therapeutic target toward HCC. Altogether, our results establish a critical role of FXYD6 in HCC progression and suggest that the therapy targeting FXYD6 can benefit the clinical treatment toward HCC patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Cell Movement
/
Sodium-Potassium-Exchanging ATPase
/
Carcinoma, Hepatocellular
/
Xenograft Model Antitumor Assays
/
Cell Line, Tumor
/
Tumor Burden
/
Cell Proliferation
/
Drug Therapy
/
HEK293 Cells
Limits:
Animals
/
Female
/
Humans
Language:
English
Journal:
Protein & Cell
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS